We're developing a pluripotent stem cell biobank, a next-generation genometric data repository, and regenerative cell production platform to support the development of regenerative cell therapies to treat severe spinal cord damage and immunological disorders, like blood diseases, cancers, sickle cell anemia, and auto-immune disorders.
AutoRegenic is a precision biomedicine manufacturing company that is productizing tissue regeneration treatments for severe spinal cord injury and immunological disorders—like quadriplegia, sickle cell anemia and blood cancers—based on its manufacturing, specialization and formulation of regenerative stem cells.
Severe spinal cord injury (SCI) creates over 15,000 comprehensive quadriplegics per year, joining the over 600,000 existing victims whose lifetime palliative care costs range from $1.5 million to $5 million.
Sickle cell disease affects millions of people of African origin worldwide, killing over 115,000 each year. Blood cancer attacks over 1.2 million people and claims around 700,000 lives per year.
AutoRegenic cell manufacturing is designed to be a safe, effective, ethically balanced, and affordable set of processes that encompass cell harvesting, culturing and differentiating. In the case of SCI the result is an optimal mix of key neuronal stem cells, blended in a biodegradable scaffold, and made available to specialist medical practitioners for transplantation into spinal column. For treating immunological disorders, a similar process, but this time involving therapeutic cloning, is employed to produce re-originated hematopoietic stem cells with which patients’ faulty immune and blood-generating systems may be refurbished.
The AutoRegenic biomedicine will be both broad and precise, treating the very source of the diseases, rather than their cascade of secondary effects. The lab service aims to address the main challenges in treating SCI and immunological diseases.
Our team is comprised of experienced entrepreneurs from the biomedical, pharmaceutical, donor registry, technology, regulatory and marketing fields, supported by a world-class scientific advisory board, including international experts in the field of regenerative medicine and transplantation, and uniquely skilled laboratory technicians.
We are busy productizing an unique set of laboratory techniques, processes, materials, and international logistics for producing naive pluripotent stem cells that promise to become a safe, effective, ethically balanced and affordable innovation of neuronal and blood stem cell sourcing and transplants on a patient-specific basis.
Following years of unique insights into regenerative therapies, the leadership team has defined a path for translating proven applied R&D and commercializing biomedicines and has assembled a set luminary supporters and advisory spanning the scientific and medical academic, as well as clinical practice, fields.